No Research and Development Activities
First written in FY2017. 4 of 8 entries say "Restated". Latest entry: FY2026-H1.
3 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「For the in-house organic synthesis system developed in collaboration with the SI business, we will begin full-scale sales activities at exhibitions held during the third quarter of the fiscal year ending November 2026.」
従来の研究開発活動の記載から、SI事業と連携して開発した自社製品について、展示会を起点とする本格販売の予定を具体化している。 - 2026-03-31AdvancedEarnings
「In cooperation with the SI business, we are proceeding with the development of an internally developed organic synthesis system scheduled to begin sales during the second quarter of the fiscal year ending November 2026.」
For internally developed products, the Company has specified the planned sales launch period for its internally developed organic synthesis system and its collaboration with the SI business. - FY2025ReframedAnnual report
「当連結会計年度における当社グループが支出した研究開発費の総額は5,018千円であり、サイエンス事業においては、安定的な収益確保を目指しつつ、長期的な事業成長を図るため、自社製品の開発を進めております。」
従来の「研究開発活動について該当事項なし」から、サイエンス事業で5,018千円の研究開発費を支出し、自社製品開発を進める記載へ変化している。 - FY2022RestatedAnnual report
「No applicable items.」
The disclosure continues to state that there are no applicable matters concerning research and development activities. - FY2020RestatedAnnual report
「No applicable items.」
The disclosure continues to state that there are no applicable matters concerning research and development activities. - FY2019RestatedAnnual report
「No applicable items.」
The disclosure continues to state that there are no applicable matters concerning research and development activities. - FY2018RestatedAnnual report
「No applicable items.」
The disclosure continues to state that there are no applicable matters concerning research and development activities. - FY2017First statedAnnual report
「No applicable items.」
The company states that there were no applicable research and development activities.